Document Detail

Monitoring of acute myeloid leukemia by flow cytometry.
MedLine Citation:
PMID:  12895393     Owner:  NLM     Status:  MEDLINE    
Monitoring of minimal residual disease (MRD) becomes increasingly important in the risk-adapted management of patients with acute myeloid leukemia (AML). In selected patients with AML, multiparameter flow cytometry has shown accuracy and sensitivity in the quantification of MRD levels with independent prognostic impact. The applicability of this approach is superior to that of other methods such as quantitative polymerase chain reaction: Up to 80% of all patients can be monitored by flow cytometry. Nonetheless, significant technical advances are anticipated to extend the applicability of flow cytometry to 100% and to improve its sensitivity. Large clinical trials will determine the role of immunologic monitoring in the prognostic stratification of patients with AML.
Wolfgang Kern; Susanne Schnittger
Related Documents :
12743153 - Significant correlation between the degree of wt1 expression and the international prog...
3971043 - Treatment of hairy cell leukemia with recombinant alpha 2 interferon.
2829643 - Otosclerosis: a local manifestation of a generalized connective tissue disorder?
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current oncology reports     Volume:  5     ISSN:  1523-3790     ISO Abbreviation:  Curr Oncol Rep     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-08-04     Completed Date:  2004-04-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100888967     Medline TA:  Curr Oncol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  405-12     Citation Subset:  IM    
Laboratory for Leukemia Diagnostics, Ludwig-Maximilians-University, University Hospital Grosshadern, Department of Internal Medicine III, 81366 Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Antigens, CD45
Flow Cytometry*
Leukemia, Myelomonocytic, Acute / immunology*,  therapy
Monitoring, Immunologic*
Neoplasm, Residual
Polymerase Chain Reaction
Sensitivity and Specificity
Reg. No./Substance:
EC, CD45

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia.
Next Document:  Immunologic monitoring in adults with acute lymphoblastic leukemia.